Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 87 (1), 21-38

Coumarin: A Privileged Scaffold for the Design and Development of Antineurodegenerative Agents

Affiliations
Review

Coumarin: A Privileged Scaffold for the Design and Development of Antineurodegenerative Agents

Ehtesham Jameel et al. Chem Biol Drug Des.

Abstract

Drug development for neurodegenerative diseases (NDs) is foremost task for the medicinal chemists in the 21st century. Coumarins are exemplary of an assorted and aptitudinally useful set of drugs. Coumarins play a momentous role in several pharmacological and medicinal aspects. Its analogues are anticipated to play a significant role in the development of new therapeutic leads for NDs. Their promising applications in the field of ND medication are exemplified by clinical candidates such as nodakenin that have been potent for demoting memory impairment. Apart from ND, clinically used anticoagulant warfarin, anticoagulant dicoumarol, and antibiotic coumermycin, novobiocin and chartesium grab the interest of researchers in coumarins. It would be worthwhile to look at the different biological processes that could cause neurodegeneration, thereby establishing a link with distinct coumarin derivatives to serve the purpose of medication. This review undertakes estimation of the wide spectrum of studies focusing coumarin to the domain of drug research for ND. Herein, we search for multitarget coumarin-based inhibitors and their scope for NDs. Future challenges in coumarin-based drug development have been discussed, and emphases have been laid on the future perspectives of coumarins as possible drugs in the future for the treatment of NDs.

Keywords: MAO; ROS; acetylcholinesterase inhibitors; coumarin; neurodegenerative diseases; oxidative stress.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

MeSH terms

Feedback